Are lecanemab and donanemab disease‐modifying therapies?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Are lecanemab and donanemab disease‐modifying therapies?

Published:2024-08-03 Issue: Volume: Page:
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Daly Timothy¹²^ORCID,Kepp Kasper P.³,Imbimbo Bruno P.⁴

Affiliation:

1. Bioethics Program FLACSO Argentina Tucumán Buenos Aires Argentina

2. Science Norms Democracy UMR 8011 Sorbonne University Paris France

3. Section of Biophysical and Biomedicinal Chemistry Kongens Lyngby Denmark

4. Research & Development Chiesi Farmaceutici Parma Italy

Publisher

Wiley

Reference15 articles.

1. Lecanemab in early Alzheimer's disease;Dyck CH;N Engl J Med,2023

2. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER‐ALZ 2 Randomized Clinical Trial;Sims JR;JAMA,2023

3. Defining and labeling disease‐modifying treatments for Alzheimer's disease;Cummings JL;Alzheimers Dement,2009

4. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics;Karran E;Nat Rev Drug Discov,2022

5. Associations between surrogate markers and clinical outcomes for nononcologic chronic disease treatments;Wallach JD;JAMA,2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP